pi3k-in-10

PI3K-IN-10 is a potent inhibitor of pan-PI3K .

AOD9604 acetate(221231-10-3 free base) 是一种基于人类生长激素的潜在抗肥胖肽。

Cathepsin K inhibitor3 是一种高选择性的cathepsin K 抑制剂，其IC50值为 0.5 nM。Cathepsin K inhibitor3 具有良好的药代动力学特征，可用于骨关节炎 (OA) 疾病的研究。

K-Ras ligand-Linker Conjugate 3 (Compound 001371) is a chemical compound that consists of a ligand for K-Ras recruiting moiety and a PROTAC linker, responsible for recruiting E3 ligases (e.g., VHL, CRBN, MDM2, and IAP). This compound is essential in the synthesis of PROTAC K-Ras Degrader-1, a potent PROTAC K-Ras degrader that demonstrates a degradation efficacy of ≥70% in SW1573 cells[1].

Heterocyclic compounds as covalent inhibitors of G12C mutant K-Ras protein useful for treating cancers.K-Ras G12C-IN-3 is a novel and irreversible inhibitor of mutant K-ras G12C.

20)abeotaxa-4(20),11-dien-10-one'>2alpha,7beta,13alpha-Triacetoxy-5alpha-cinnamoyloxy-9beta-hydroxy-2(3->20)abeotaxa-4(20),11-dien-10-one 是一种天然产物，可用于生命科学领域的相关研究。其产品编号为 TN2840，CAS号为 322471-42-1。

8,9-Epoxy-3-isobutyryloxy-10-(2-methylbutanoyl)thymol is a chemical composition of essential oils from Telekia speciosa. It also shows marked antipro-liferative activity against human cancer cell lines in vitro.

PI3Kδ-IN-10 是高效的、具有口服活性的PI3Kδ抑制剂（IC50= 2 nM）。在肝细胞癌模型中，PI3Kδ-IN-10 强烈抑制下游AKT 通路，并诱导细胞凋亡(apoptosis)。

3,4-Seco-3-oxobisabol-10-ene-4,1-olide 是一种天然产物，可用于生命科学领域的相关研究。其产品编号为 TN5372，CAS号为 1564265-85-5。

TNF-α (10-36), human (TFA) is a peptide of human TNF-α.

K 259-3 是 K 259-2 的甲酯，是钙调素依赖性环核苷酸磷酸二酯酶的抑制剂。

3-(2'-Deoxyribofuranosyl)pyrimido(1,2-a)purin-10(3H)-one is a malondialdehyde-deoxyguanosine adduct.

Lup-20(29)-en-28-oic acid, 3-hydroxy-, 10-carboxydecyl ester, (3beta)- is a bioactive chemical.

PI3K-IN-51, characterized as a PI3K inhibitor, exhibits IC50 values below 500 nM for p120γ and p110δ p85α (WO2016204429A1; Example 10) [1].

PI3K/mTOR Inhibitor-7 是有效的 PI3K/mTOR 双重抑制剂。PI3K/mTOR Inhibitor-7 的作用比 gedatolisib 高 4.7 倍，他们的 IC50 值分别为 1.4 μM 和 0.3 μM。10 μM 的 PI3K/mTOR Inhibitor-7 能够明显抑制 PI3K/Akt/mTOR 信号通路。PI3K/mTOR Inhibitor-7 对癌症疾病表现出研究潜力。

The Immuno-Oncology Screening Library consists of 2 plates and contains more than 90 cancer and immunology-associated compounds in a 96-well Matrix tube rack format as 10 mM stock solutions in DMSO. This library includes a variety of immuno-oncology target modulators, including but not limited to, adenosine, CCR, CXCR, and TLR agonists and antagonists, BTK, PI3K, VEGFR, and BRAF inhibitors, PD-1/PDL-1 interaction inhibitors, and HDAC inhibitors. Please review the product insert for a full list of targets. Stability data is not available for the compounds as supplied in the screening library.

PLM-101是一种口服抗癌剂，针对FLT3和RET具有选择性抑制作用，有效抑制急性髓系白血病（AML）细胞。通过抑制RET，PLM-101促使FLT3的自噬降解，并且通过抑制PI3K和Ras/ERK信号通路来发挥其抗白血病的活性。在小鼠MV4-11侧翼异种移植模型中，PLM-101以口服剂量3及10 mg/kg显示出抗肿瘤效果，并且在同种异种移植小鼠模型中，剂量为40 mg/kg（口服）亦展现出明显的抗肿瘤功效。

PF-06843195 is a highly selective PI3Kα inhibitor with an IC50 of 18 nM in Rat1 fibroblasts. The Kis of PF-06843195 for PI3Kα and PI3Kδ in biochemical kinase assay are less than 0.018 nM and 0.28 nM, respectively. PF-06843195 has great suppression of the PI3K mTOR signaling pathway and durable antitumor efficacy[1]. PF-06843195 inhibits the breast cancer cell lines MCF7 and T47D proliferation with IC50s of 62 nM and 32 nM, respectively[1].PF-06843195 inhibits pAKT (T308) in MCF7 and T47D cells with IC50s of 7.8 nM and 8.7 nM, respectively[1]. In rats, PF-06843195 can rapidly and quantitatively transform from PF-06862309[1].PF-06843195 exhibits oral bioavailability (rat 25 %) following oral administration (rat 10 mg kg)[1].PF-06843195 exhibits a moderate half-life (rat 3.6 h) due to high plasma clearance (30 mL min kg) combined with large volumes of distribution (3.0 L kg) following intravenous administration (rat 2 mg kg)[1]. [1]. Hengmiao Cheng, et al. Structure-Based Drug Design and Synthesis of PI3Kα-Selective Inhibitor (PF-06843195). J Med Chem. 2021 Jan 14;64(1):644-661.

PI3K-IN-23 是一种 (E)-9-oxooctadec-10-en-12-ynoic acid 类似物，能够促进葡萄糖摄取 (EC50: 7.00 μM)。

PI3K mTOR Inhibitor-6 (Compound 19c) 是一种有效的 PI3K mTOR 双重抑制剂，在人工胃液中的稳定性比 gedatolisib 更高。10 μM 的 PI3K mTOR Inhibitor-6 能够明显抑制 PI3K Akt mTOR 信号通路。PI3K mTOR Inhibitor-6 对癌症疾病表现出研究潜力。

AKT-IN-10 是有效的 AKT 抑制剂，对乳腺癌和前列腺癌表现出研究潜力。其中蛋白激酶 B (PKB，也称为 AKT) 是细胞中 PI3K AKT mTOR 信号传导的核心，其功能对细胞生长、存活、分化和代谢很重要。

Antileishmanial agent-19 (Compound F27)是一种有效的抗利什曼病试剂，其对L. donovani promastigotes的IC50值为3.39 μM。该化合物能够抑制L. donovani promastigotes中的脯氨酰-tRNA合成酶，并干预宿主PI3K/Akt/CREB轴，从而抑制IL-10的分泌。此外，Antileishmanial agent-19能诱导L. donovani promastigotes自噬介导的细胞凋亡(apoptosis)过程，并在感染的动物体内显著减少寄生虫负担。